Zobrazeno 1 - 10
of 10
pro vyhledávání: '"76"'
Autor:
Valentina Viggiani, Piero Chirletti, S Tartaglione, Patrizia Mancini, Emanuela Anastasi, Antonio Angeloni
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251656 (2021)
PLoS ONE
PLoS ONE
Background Pancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC bio
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0173242 (2017)
PLoS ONE
PLoS ONE
Background DNA methylation is a stable epigenetic mark that is frequently altered in tumors. DNA methylation features are attractive biomarkers for disease states given the stability of DNA methylation in living cells and in biologic specimens typica
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0187635 (2017)
PLoS ONE
PLoS ONE
Invasion and metastasis are direct causes of mortality in patients with breast cancer and require reciprocal interactions between cancer cells and the extracellular matrix (ECM). Periostin, a fasciclin-containing adhesive ECM glycoprotein, is frequen
Autor:
Eleni Lagoudaki, Eleftheria-Kleio Dermitzaki, John Souglakos, Athanasios Kotsakis, Vassilis Georgoulias, Eleni Politaki, Anastasios Koutsopoulos, Filippos Koinis, Ippokratis Messaritakis, Galatea Kallergi
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0181211 (2017)
PLoS ONE
PLoS ONE
Background To evaluate the phenotypic heterogeneity of circulating tumor cells (CTCs) based on the expression of proliferative, apoptotic and Epithelial-to-Mesenchymal Transmission (EMT) markers during front-line treatment in patients with small cell
Autor:
Ping-cheng Yuan, Wei-dong Jiang
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 8, p e0220118 (2019)
PLoS ONE, Vol 14, Iss 8, p e0220118 (2019)
BackgroundCircular RNAs (circRNAs) have been shown to interact with microRNAs (miRNA) as competitive endogenous RNAs (ceRNAs) to regulate target gene expression and participate in tumorigenesis. However, the role of circRNA-mediated ceRNAs in bladder
Autor:
Seung Hyup Hyun, Jeong Eon Lee, Kyung-Han Lee, Joon Young Choi, Yeon Hee Park, Joo Hee Lee, Young-Hyuck Im, Seok Jin Nam, Byung-Tae Kim, Hee Kyung Ahn
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0165814 (2016)
PLoS ONE
PLoS ONE
Purpose To investigate the combined prognostic impact of body mass index (BMI) and tumor standardized uptake value (SUV) measured on pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in patients with br
Autor:
Thomas Lacornerie, David Pasquier, Philippe Nickers, Eric Lartigau, Pascal Pommier, Philippe Maingon, Geoffrey Martinage, Emmanuelle Tresch, Didier Peiffert
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 11, p e0187794 (2017)
PLoS ONE, Vol 12, Iss 11, p e0187794 (2017)
Purpose Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multicenter national program was developed to assess toxicity and tumor response with hypofractionated stereotactic boost after conventional radiotherapy in int
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0181926 (2017)
PLoS ONE
PLoS ONE
At least seven studies have suggested that microRNA levels in whole blood can be diagnostic for lung cancer. We conducted a large bi-institutional study to validate this. Qiagen® PAXgene™ Blood miRNA System was used to collect blood and extract RN
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 2, p e0172155 (2017)
PLoS ONE, Vol 12, Iss 2, p e0172155 (2017)
Background Among various reconstruction methods after wide excision for osteosarcoma, pasteurized autograft is often preferred. While the whole area of the tumor can be assessed for chemotherapy-induced necrosis, one of the important prognostic facto
Autor:
Nehad M. Alajez
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0167455 (2016)
PLoS ONE
PLoS ONE
Colorectal cancer (CRC) is the fourth-ranked cause of cancer-related deaths worldwide. Despite recent advances in CRC management, distant recurrence (DR) remains the major cause of mortality in patients with preoperative chemotherapy and radiotherapy